{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:02:07Z","timestamp":1787068927612,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010814","name":"Anhui Province Department of Education","doi-asserted-by":"publisher","award":["2022AH020052"],"award-info":[{"award-number":["2022AH020052"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2308085Y51"],"award-info":[{"award-number":["2308085Y51"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2020xkjT009"],"award-info":[{"award-number":["2020xkjT009"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2022sfy017"],"award-info":[{"award-number":["2022sfy017"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bcp.2024.116066","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:04:48Z","timestamp":1708167888000},"page":"116066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects"],"prefix":"10.1016","volume":"222","author":[{"given":"Yizhao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weile","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2024.116066_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116066_b0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3389\/fimmu.2017.01117","article-title":"Human Tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision","volume":"8","author":"Adair","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010059","article-title":"Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2024.116066_b0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.bcp.2024.116066_b0035","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA approval of remdesivir - A step in the right direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2024.116066_b0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"24","key":"10.1016\/j.bcp.2024.116066_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.9925","article-title":"FDA grants full approval to paxlovid, COVID-19 antiviral treatment","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"6602","key":"10.1016\/j.bcp.2024.116066_b0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1126\/science.add8037","article-title":"Bad news for Paxlovid? Resistance may be coming","volume":"377","author":"Service","year":"2022","journal-title":"Science (New York, N.Y.)"},{"issue":"7944","key":"10.1016\/j.bcp.2024.116066_b0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116066_b0060","doi-asserted-by":"crossref","unstructured":"M.I. Barton, S.A. MacGowan, M.A. Kutuzov, O. Dushek, G.J. Barton, P.A. van der Merwe, Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics, eLife 10 (2021).","DOI":"10.7554\/eLife.70658"},{"issue":"7","key":"10.1016\/j.bcp.2024.116066_b0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"7948","key":"10.1016\/j.bcp.2024.116066_b0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0075","article-title":"Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2","volume":"20","author":"Li","year":"2022","journal-title":"J. Transl. Med."},{"issue":"635","key":"10.1016\/j.bcp.2024.116066_b0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm7853","article-title":"Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"7807","key":"10.1016\/j.bcp.2024.116066_b0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41422-021-00595-6","article-title":"Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2","volume":"32","author":"Gu","year":"2022","journal-title":"Cell Res."},{"issue":"49","key":"10.1016\/j.bcp.2024.116066_b0095","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd7114","article-title":"Comprehensive mapping of immune perturbations associated with severe COVID-19","volume":"5","author":"Kuri-Cervantes","year":"2020","journal-title":"Sci. Immunol."},{"issue":"6508","key":"10.1016\/j.bcp.2024.116066_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12967-021-03159-9","article-title":"Virus infection induced pulmonary fibrosis","volume":"19","author":"Huang","year":"2021","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2024.116066_b0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/rme.14.35","article-title":"Cell-based therapy approaches: the hope for incurable diseases","volume":"9","author":"Buzhor","year":"2014","journal-title":"Regen. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2024.116066_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031716","article-title":"SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19","volume":"23","author":"Gusev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2024.116066_b0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2024.116066_b0130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3389\/fphar.2020.01309","article-title":"Harnessing memory NK cell to protect against COVID-19","volume":"11","author":"Soleimanian","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116066_b0135","doi-asserted-by":"crossref","unstructured":"Q. Chen, A. Chia, S.K. Hang, A. Lim, W.K. Koh, Y. Peng, F. Gao, J. Chen, Z. Ho, L.E. Wai, K. Kunasegaran, A.T. Tan, N. Le Bert, C.Y. Loh, Y.S. Goh, L. Renia, T. Dong, A. Vathsala, A. Bertoletti, Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy, Cellular & molecular immunology (2023).","DOI":"10.1038\/s41423-023-01080-3"},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0140","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","article-title":"Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond","volume":"44","author":"Bittner","year":"2023","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2024.116066_b0145","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-023-01621-y","article-title":"Vaccine-induced CD8(+) T cells are key to protection from SARS-CoV-2","volume":"24","author":"Antoun","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2024.116066_b0150","doi-asserted-by":"crossref","DOI":"10.1017\/S095026882200125X","article-title":"Innate immunity to SARS-CoV-2 infection: a review","volume":"150","author":"Silva","year":"2022","journal-title":"Epidemiol. Infect."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12967-020-02520-8","article-title":"Pathophysiology and treatment strategies for COVID-19","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bcp.2024.116066_b0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MCP.0000000000000953","article-title":"Drug treatment of COVID-19 infection","volume":"29","author":"Lui","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13613-020-00661-z","article-title":"Therapeutic strategies for critically ill patients with COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.bcp.2024.116066_b0170","unstructured":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet (London, England) 397(10289) (2021) 2049-2059."},{"key":"10.1016\/j.bcp.2024.116066_b0175","doi-asserted-by":"crossref","unstructured":"X. Rao, R. Zhao, Z. Tong, S. Guo, W. Peng, K. Liu, S. Li, L. Wu, J. Tong, Y. Chai, P. Han, F. Wang, P. Jia, Z. Li, X. Zhao, D. Li, R. Zhang, X. Zhang, W. Zou, W. Li, Q. Wang, G.F. Gao, Y. Wu, L. Dai, F. Gao, Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2, Proceedings of the National Academy of Sciences of the United States of America 120(52) (2023) e2314193120.","DOI":"10.1073\/pnas.2314193120"},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nature Metab."},{"key":"10.1016\/j.bcp.2024.116066_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108655","article-title":"COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches","volume":"107","author":"Zavvar","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2024.116066_b0195","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.bcp.2024.116066_b0200","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker","year":"2022","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41584-023-00968-8","article-title":"Chimeric receptors broaden the therapeutic landscape for autoimmune disease","volume":"19","author":"Finkel","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"14","key":"10.1016\/j.bcp.2024.116066_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411803","article-title":"CAR-T state of the art and future challenges, A regulatory perspective","volume":"24","author":"Giorgioni","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2024.116066_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115497","article-title":"Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression","volume":"22","author":"Khanam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7847","key":"10.1016\/j.bcp.2024.116066_b0220","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2024.116066_b0225","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202187","article-title":"Mapping and role of T cell response in SARS-CoV-2-infected mice","volume":"218","author":"Zhuang","year":"2021","journal-title":"J. Exp. Med."},{"issue":"7898","key":"10.1016\/j.bcp.2024.116066_b0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0235","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2024.116066_b0240","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0245","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116066_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087641","article-title":"Specific activation of T cells by an ACE2-based CAR-like receptor upon recognition of SARS-CoV-2 spike protein","volume":"24","author":"Gonzalez-Garcia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116066_b0255","doi-asserted-by":"crossref","unstructured":"X. Guo, A. Kazanova, S. Thurmond, H.U. Saragovi, C.E. Rudd, Effective chimeric antigen receptor T cells against SARS-CoV-2, iScience 24(11) (2021) 103295.","DOI":"10.1016\/j.isci.2021.103295"},{"issue":"10","key":"10.1016\/j.bcp.2024.116066_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1421","article-title":"Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2","volume":"11","author":"Dogan","year":"2022","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12951-021-01148-0","article-title":"Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19","volume":"19","author":"Zhu","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116066_b0270","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural killer cell deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2024.116066_b0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","article-title":"Natural killer cell-mediated immunosurveillance of human cancer","volume":"31","author":"Malmberg","year":"2017","journal-title":"Semin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0280","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41577-021-00558-3","article-title":"Natural killer cells in antiviral immunity","volume":"22","author":"Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.bcp.2024.116066_b0285","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1182\/bloodadvances.2020002650","article-title":"Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19","volume":"4","author":"Osman","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2024.116066_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0295","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01354-3","article-title":"New insights into the stemness of adoptively transferred T cells by \u03b3c family cytokines","volume":"21","author":"Luo","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0300","article-title":"Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19","volume":"13","author":"Lu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116066_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652223","article-title":"CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116066_b0310","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.RA120.002295","article-title":"Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cell. Proteom.: MCP"},{"key":"10.1016\/j.bcp.2024.116066_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763460","article-title":"Glycoprotein targeted CAR-NK Cells for the treatment of SARS-CoV-2 infection","volume":"12","author":"Christodoulou","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116066_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092821","article-title":"Monocytes and macrophages as viral targets and reservoirs","volume":"19","author":"Nikitina","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2024.116066_b0325","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2024.116066_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763313","article-title":"Macrophage activation syndrome and COVID 19: impact of MAPK driven immune-epigenetic programming by SARS-Cov-2","volume":"12","author":"Roy","year":"2021","journal-title":"Front. Immunol."},{"issue":"7914","key":"10.1016\/j.bcp.2024.116066_b0335","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"issue":"664","key":"10.1016\/j.bcp.2024.116066_b0340","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3059","article-title":"SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery","volume":"14","author":"Frere","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"26","key":"10.1016\/j.bcp.2024.116066_b0345","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1016\/j.cell.2021.11.033","article-title":"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis","volume":"184","author":"Wendisch","year":"2021","journal-title":"Cell"},{"issue":"10270","key":"10.1016\/j.bcp.2024.116066_b0350","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2024.116066_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669103","article-title":"CAR Macrophages for SARS-CoV-2 Immunotherapy","volume":"12","author":"Fu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0360","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-020-00426-x","article-title":"CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0365","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","article-title":"AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0375","first-page":"20","article-title":"Transmembrane domains participate in functions of integral membrane proteins","volume":"33","author":"Ramasarma","year":"1996","journal-title":"Indian J. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116066_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.bcp.2024.116066_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bcp.2024.116066_b0390","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt-2019-0017","article-title":"TREM1\/Dap12-based CAR-T cells show potent antitumor activity","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.bcp.2024.116066_b0395","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2024.116066_b0400","doi-asserted-by":"crossref","unstructured":"M.L. Bettini, P.C. Chou, C.S. Guy, T. Lee, K.M. Vignali, D.A.A. Vignali, Cutting Edge: CD3 ITAM diversity is required for optimal TCR signaling and thymocyte development, J. Immunol. (Baltimore, Md. : 1950) 199(5) (2017) 1555-1560.","DOI":"10.4049\/jimmunol.1700069"},{"issue":"7952","key":"10.1016\/j.bcp.2024.116066_b0405","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bcp.2024.116066_b0410","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","article-title":"Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2024.116066_b0415","article-title":"A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy","author":"Hirayama","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bcp.2024.116066_b0420","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116066_b0425","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"43","key":"10.1016\/j.bcp.2024.116066_b0430","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"issue":"7897","key":"10.1016\/j.bcp.2024.116066_b0435","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116066_b0440","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.omtm.2020.12.008","article-title":"Automated generation of gene-edited CAR T cells at clinical scale","volume":"20","author":"Alzubi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Devel."},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0445","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","article-title":"Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products","volume":"38","author":"Sadeqi Nezhad","year":"2021","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0455","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14712598.2017.1316713","article-title":"Advances in umbilical cord blood cell therapy: the present and the future","volume":"17","author":"Berglund","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bcp.2024.116066_b0460","article-title":"Engineering NK cells for CAR therapy-recent advances in gene transfer methodology","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116066_b0465","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol. Ther. Methods Clin. Devel."},{"issue":"19","key":"10.1016\/j.bcp.2024.116066_b0470","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"issue":"6","key":"10.1016\/j.bcp.2024.116066_b0475","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061337","article-title":"Transposon-based CAR T cells in acute leukemias: Where are we going?","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116066_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032397","article-title":"Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies","volume":"13","author":"Singh","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116066_b0485","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.bcp.2024.116066_b0490","doi-asserted-by":"crossref","first-page":"18408","DOI":"10.1021\/acsnano.2c06516","article-title":"Ganglioside-functionalized nanoparticles for chimeric antigen receptor T-cell activation at the immunological synapse","volume":"16","author":"Zang","year":"2022","journal-title":"ACS Nano"},{"issue":"656","key":"10.1016\/j.bcp.2024.116066_b0495","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116066_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0505","article-title":"Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2024.116066_b0510","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2024.116066_b0515","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","article-title":"Emerging treatment strategies for COVID-19 infection","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0520","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25479-6","article-title":"Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum","volume":"12","author":"Bates","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg. Microb. Infect."},{"issue":"3","key":"10.1016\/j.bcp.2024.116066_b0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.bcp.2024.116066_b0535","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.chom.2022.09.018","article-title":"Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75","volume":"30","author":"Cao","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bcp.2024.116066_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101508","article-title":"Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion","volume":"55","author":"Mazzoni","year":"2021","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116066_b0545","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03328-4","article-title":"Autoimmunity is a hallmark of post-COVID syndrome","volume":"20","author":"Rojas","year":"2022","journal-title":"J. Transl. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:44:07Z","timestamp":1778629447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":109,"alternative-id":["S0006295224000492"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116066","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116066"}}